FibMAb

N/A

Report date: 2022/08/23 20:00:44

Base Information

Drug NameFibMAb
Drug Alias NameP2-19
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAngiogenesis inhibitors
TargetsUpdating
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesJanssen Vaccines Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJanssen Vaccines Corp
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A